-
Innovation
Turbocharging the effect of vaccines
When extracted and purified, a compound from the soap bark tree can be mixed with other ingredients to create an ‘adjuvant’, turbocharging the body's immune defences.
-
Innovation
Vaccine manufacture: it’s complicated
Vaccine manufacture can take anywhere between 6 and 26 months. That’s not to mention the time required to research and develop a new vaccine, which can take up to 30 years.
-
Innovation
Welcome to the golden age of vaccine innovation
Join our leading scientists as they go behind the science of one of the most-effective interventions in modern medicine
-
Access to healthcare
No 'silver bullet' to tackle this disease
The combination of increased funding, resources and education to fight malaria have contributed to a reduction in deaths from this mosquito-borne disease.
-
Access to healthcare
Life after polio: Fatiha's story
Fatiha describes her experience of polio and why she wanted to work for GSK.
-
Access to healthcare
Ebola vaccine R&D
Learn how we are advancing the development of our GSK/NIH Ebola vaccine candidate.
-
Access to healthcare
Ebola: our fast track response
GSK responded to the crisis by contributing humanitarian support and accelerating the development of an investigational Ebola vaccine.
-
Access to healthcare
Fighting Ebola highlights the need for more health workers
The Ebola crisis is by far the worst outbreak of the disease the world has ever seen.
-
Access to healthcare
Forming public partnerships
The Ebola crisis has been an unusual and rapidly changing situation. Find out how we are responding.
-
Access to healthcare
On the frontline of Ebola prevention
Read how Robbie worked on the ground to fight Ebola.
-
Access to healthcare
Health workers fighting it on the frontline
Almost everyone in Tanzania is at risk of malaria. The mosquito-borne disease is responsible for more than 10% of deaths among children under five in this East African country.
-
Access to healthcare
Our humanitarian response to the Ebola outbreak
GSK's ongoing efforts to strengthen healthcare infrastructure in the most affected countries.
-
Access to healthcare
Guardian article: The 30-year quest for a malaria vaccine
Dr Joe Cohen recalls his experiences of being part of the team to develop what could be the world’s first vaccine against malaria
-
Access to healthcare
Why are we fighting malaria in the lab and on the ground?
Despite progress to fight malaria, millions of people continue to suffer every year. We’re helping by researching medicines and vaccines, supporting community prevention and health worker training and strengthening access to medicines.
-
Access to healthcare
Vaccines - coming in from the cold
‘Thermostability’ - it may sound very technical and complicated, but really it’s all about fridges.
-
Access to healthcare
Making our vaccines more accessible
We are determined to use our resources, knowledge and expertise to help improve access to immunisation.
-
Access to healthcare
TEDMED 2015: Art, inspired by vaccination
A blank canvas, Unformed clay. An empty petri dish.
-
Access to healthcare
TEDMED 2015: An interview with curator, Christine McNab
We interview Christine McNab, curator of The Art of Saving a Life.
-
Access to healthcare
The value of vaccination
According to the World Health Organization, only clean drinking water rivals vaccination in its ability to save lives.
-
Access to healthcare
Rabies – Educate, Vaccinate, Eliminate.
28 September is World Rabies Day, when organisations across the globe, all with the common goal of eliminating human deaths from rabies by 2030, work together to raise awareness of this ‘neglected tropical disease’ under the theme ‘Educate, Vaccinate, Eliminate’.
-
Access to healthcare
Taking action to stop pneumonia
Pneumonia is a preventable and treatable disease.
-
Patients & consumers
Eggs in manufacturing
Chickens. Where would we be without them? Well for one thing, we wouldn’t have nearly as many influenza vaccines as we need.
-
Patients & consumers
Helping to protect yourself against flu
Influenza, commonly called ‘the flu’, is a contagious infection of the respiratory tract, which affects people of all ages.
-
Patients & consumers
Win for Meningitis – harnessing the power of inspirational images to create a win for disease prevention
Through our Win for Meningitis campaign, we’re helping to raise awareness of this damaging disease.
-
Patients & consumers
Maternal immunisation: Helping protect mums and babies
Immunisation during pregnancy can help protect the mother, and also help protect the baby before birth and through the critical first few weeks of life.
-
Patients & consumers
You'll outgrow some childhood habits, but vaccination is for life
Infectious diseases remain just as serious throughout adulthood and vaccines remain the most effective protection we have against them.
-
Our people
Beyond manufacturing in Chile and Madagascar
In 2015, GSK Vaccines sent two vaccine manufacturing teams to South America and Africa to better understand the impact of their daily work.
-
Our people
Tackling tomorrow’s health challenges today
Our Chief Scientist, Rino Rappuoli, explains how science is helping create the vaccines of tomorrow
-
How we do business
Why our transaction with Novartis is different
What makes GSK’'s transaction with Novartis different?
-
How we do business
The power of partnerships: transforming vaccine coverage in Mozambique
More than 35,000 children in the northern Mozambique province of Nampula are now registered with the mVacciNation pilot programme that was rolled out in 2015 by GSK and Vodafone, with funding from GAVI and USAID.
